Aluminum Hydroxide
Severe
Database
Clinical effect not specified
Source: DDInter
Drug reference
Raltegravir
Antiretroviral · HIV infection
Also known as RAL
AntiretroviralHIV infection
CDSCO approvedSchedule H
EXCRETION
—
not curated
INTERACTIONS
9 major
SEVERE in our sources
PREGNANCY
g Management of HIV infection in pregnancy should
FDA category + note
Top interactionssee all 12 →
- Aluminum HydroxideSevereDatabaseDDInter
- Calcium CarbonateSevereDatabaseDDInter
- MagaldrateSevereDatabaseDDInter
- Magnesium HydroxideSevereDatabaseDDInter
Mechanism
Raltegravir is an HIV integrase strand transfer inhibitor (INSTI) that blocks the catalytic activity of HIV integrase by chelating the essential divalent metal ions (Mg²⁺) at the enzyme's active site, preventing the integration of viral DNA into the host cell chromosome. This arrests the HIV replication cycle at a step after reverse transcription but before proviral DNA establishment, providing a mechanism distinct from all other antiretroviral classes. It has activity against both HIV-1 and HIV-2.
Indications
HIV infectionHIV infection, post-exposure prophylaxis (off-label)HIV-infected adults and children weighing 2 kg or moreHIV (addition to optimized background therapy in repeatedly treated patients)untreated patients as a component of initial triple drug regimen (with two NRTIs)
Dosing
- Adult
- adults with antiretroviral therapy available at www.bhiva.org/ guidelines. There can be variation in the licensing of different medicines containing the same drug.…
Pharmacokinetics
Onset
Orally active
Half-life
9
Bioavailability
≥31.8 ± 9.4%
Protein binding
83%
Metabolism
UGT1A1
Excretion
9% (renal, unchanged)
Side effects
Common
headachenauseaastheniafatiguecreatine kinase elevationsmyopathyrhabdomyolysisexacerbation of depressionnonspecific side effects (otherwise well tolerated)
Serious
- drug reaction with eosinophilia and systemic symptoms (DRESS)
- myopathy (potential toxicity)
Pregnancy & lactation
Pregnancy
g Management of HIV infection in pregnancy should
Drug interactions
Calcium Carbonate
Severe
Database
Clinical effect not specified
Source: DDInter
Magaldrate
Severe
Database
Clinical effect not specified
Source: DDInter
Magnesium Hydroxide
Severe
Database
Clinical effect not specified
Source: DDInter
Rifampicin
Severe
Database
.
Source: DDInter
Zinc Acetate
Severe
Database
Clinical effect not specified
Source: DDInter
Zinc Chloride
Severe
Database
Clinical effect not specified
Source: DDInter
Zinc Gluconate
Severe
Database
Clinical effect not specified
Source: DDInter
Zinc Sulfate
Severe
Database
Clinical effect not specified
Source: DDInter
Aluminum Containing Antacids
Moderate
Textbook
Reduced bioavailability of raltegravir.
Magnesium- or aluminum-containing antacids and sucralfate must be taken 6 h before or 2 h after raltegravir.
Source: G&G 14e · p1245-1266
Calcium Containing Supplements
Moderate
Textbook
Reduced bioavailability of raltegravir.
Administration of calcium- and iron-containing supplements should be separated from raltegravir by at least 2 h, unless given with food.
Source: G&G 14e · p1245-1266
Iron Containing Supplements
Moderate
Textbook
Reduced bioavailability of raltegravir.
Administration of calcium- and iron-containing supplements should be separated from raltegravir by at least 2 h, unless given with food.
Source: G&G 14e · p1245-1266
Related guidelines
Antiretroviral therapy for HIV
NACO · Infectious Diseases · 2018
Initial monotherapy for newly diagnosed epilepsy
ILAE · Neurology · 2013
Skin and soft tissue infections
IDSA · Infectious Diseases · 2010
Hepatitis B — chronic infection
EASL · Gastroenterology · 2025
Urinary tract infection
EAU · Urology · 2024
Other Antiretroviral drugs
Ask House about Raltegravir
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: KD Tripathi 7e, Goodman & Gilman 14e, BNF·Verified: 2026-05-13 · House clinical team